ÀüÀ̼º ¾Ç¼ºÈæ»öÁ¾¿¡ ´ëÇÑ Dimethyl Triazeno Imidazole Carboxamide (DTIC)ÀÇ Ä¡·áÈ¿°ú
Dimethyl Triazeno Imidazole Carboxamide (DTIC) Therapy in Metastatic Malignant Melanoma
¹Ú±Ùö, °À±±¸, ÀÌÀçÈÆ, ±è½ÂÅÃ, ¹æ¿µÁÖ, ±è³ë°æ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú±Ùö ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°À±±¸ ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÀçÈÆ ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è½ÂÅà ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹æ¿µÁÖ ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è³ë°æ ( )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
KMID : 0360319870190020095
Abstract
Twenty-six patients with metastatic malignant melanoma were treated with dimethyl triazeno imidazole carboxamide (DTIC), at a dose of 250 mg/§³ intravenously daily for 5 days every 3 weeks Six of 26(23%) patients achieved partial remission with a median response duration of 15 weeks The median survival from onset of thereapy was 28 weeks for all patients and 45 weeks for those who responded to chemotherapy. Toxicity was acceptable and easily controlled.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸